The clinical diagnosis of "resistant hypertension" is often a misnomer. The root cause is frequently a "resistant system" plagued by therapeutic inertia—where clinicians fail to intensify treatment for months—and poor patient follow-up. True biological resistance to medication affects only about 10-15% of these patients.
Related Insights
Successful healthcare systems like Kaiser improve blood pressure control not through better individual doctors, but by implementing system-wide solutions: standardized treatment protocols, empowered care teams, and actionable data registries. This shifts the focus from individual effort to scalable processes.
Dr. Smith contrasts allopathic medicine, which uses drugs to manage symptoms of chronic disease, with functional medicine, which investigates and addresses the underlying drivers of the problem, such as diet, allergies, or toxicity.
Many chronic illnesses, including high blood pressure, cancer, and cognitive decline, are not separate issues but symptoms of a single underlying problem: chronically elevated insulin levels. This metabolic “trash” accumulates over years, making the body a breeding ground for disease.
Clinical trials use arbitrary, time-based definitions (e.g., relapse within 2 years) for endocrine resistance. This isn't a perfect biological classification but a practical necessity to create homogeneous patient groups for testing, which may not fully reflect the diverse patient population in clinical practice.
Medicine excels at following standardized algorithms for acute issues like heart attacks but struggles with complex, multifactorial illnesses that lack a clear diagnostic path. This systemic design, not just individual doctors, is why complex patients often feel lost.
Dr. Smith argues that while drugs are essential for acute emergencies like heart attacks or broken bones, they are ill-suited for chronic problems. For long-term issues, focusing on root causes is more effective than continuous symptom management with medication.
Disparities in blood pressure control are often not caused by clinicians treating patient groups differently within a practice. Instead, they arise because certain practices, which tend to serve more minority communities, have lower control rates for all their patients. The solution is to lift the performance of the entire practice.
Relying solely on talk therapy for a physiological problem can be counterproductive. When a patient makes no progress despite their efforts, they can develop learned helplessness and self-blame, concluding they are a "failure" and worsening their condition.
The silent nature of high cholesterol creates a psychological barrier. Patients who feel perfectly healthy are often unwilling to commit to lifelong treatment, even when their risk is high, leading to preventable cardiovascular events.
The ultimate validation for a new medical treatment is when physicians themselves start using it. The high rate of GLP-1 drug use among neuroscientists and other doctors, who have the deepest understanding of the risks and benefits, is a powerful signal of the drug's effectiveness.
